● pepmg Research Desk · Peer-reviewed evidence review
What the research says about MGF
A neutral summary of the peer-reviewed literature on mechano-growth factor (MGF), a splice variant of IGF-1 studied in cell and animal models of muscle, cartilage, and neural repair. No controlled human trials, and a notable independent replication failure. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- MGF (mechano-growth factor) is a splice variant of insulin-like growth factor 1 (IGF-1): mechanical stress or injury to skeletal muscle shifts IGF-1 gene splicing to produce an isoform whose distinctive C-terminal E-domain peptide was named MGF [1][3].
- In cell and animal models, MGF and its E-peptide have been reported to stimulate muscle satellite-cell proliferation and to act in cartilage and neural tissue [1][6][7]; the evidence is entirely preclinical.
- Two pharmaceutical companies failed to reproduce the foundational claim that synthetic MGF peptide increases muscle myoblast proliferation, an independent replication failure that is important context [3].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What MGF is
Mechano-growth factor is described in the literature as a product of the IGF-1 gene. The IGF-1 pre-mRNA can be spliced in more than one way; in skeletal muscle, mechanical loading or injury up-regulates a splice variant (referred to as IGF-IEb in rodents and IGF-1Ec in humans) whose distinctive C-terminal peptide, cleaved from the mature IGF-1 protein, was termed MGF [1][3]. Because it is generated locally in response to physical activity rather than secreted systemically by the liver, MGF has been framed as a local, activity-dependent signal distinct from circulating IGF-1 [2].
The claimed biological activities center on repair: reviews describe MGF up-regulation correlating with satellite-cell and myoblast proliferation after muscle injury, positioning it as a candidate mechanism for muscle regeneration [1]. MGF has never been an approved medicine. It is studied as a research peptide, and material sold by research-chemical vendors is not an approved pharmaceutical product and is offered for laboratory and research use only.
What the preclinical research has measured
Preclinical onlyThe muscle literature is the origin of MGF. Reviews of the growth-hormone/IGF-1 axis in ageing muscle describe the activity-dependent MGF splice variant as up-regulated by physical activity and associated with satellite-cell proliferation, and propose it as relevant to sarcopenia [1][2]. These are expression and mechanism studies in muscle tissue and cell culture, not clinical trials.
Beyond muscle, MGF and its E-domain peptide have been studied in cell and animal models of other tissues. In cartilage, reviews and cell studies report that MGF is highly expressed in chondrocytes, especially in damaged cartilage, and that the MGF E-peptide can influence chondrocyte metabolism under simulated injury [5][6]. Cell studies also report effects on bone-marrow stromal cell migration and differentiation and on anterior cruciate ligament repair models [7][8]. In the brain, transgenic mice overexpressing MGF showed increased proliferation of cells in neurogenic regions of the hippocampus, and endogenous brain MGF declined with age [4].
Across this corpus, MGF evidence is preclinical throughout: expression analyses, cultured cells, and genetically modified or injured animals. No controlled human trials of MGF administration measuring muscle, cartilage, or any clinical outcome appear here.
What the studies report on safety and adverse events
Preclinical onlyBecause there are no human trials of MGF in this corpus, there is no controlled human safety or adverse-event data to report. The available studies are mechanistic work in cells and animals and do not characterize safety, tolerability, or adverse effects in people.
Two considerations belong here nonetheless. First, MGF is derived from the IGF-1 gene and its parent signaling axis (GH/IGF-1) is broadly involved in cell growth; growth-promoting signals in general warrant caution, but this corpus contains no controlled data establishing MGF's risk profile either way. Second, and importantly for honesty, the foundational muscle claim is contested: investigators at two pharmaceutical companies attempted to reproduce the reported effect of synthetic MGF peptide on human and mouse myoblast proliferation and differentiation in vitro and were unable to do so [3]. A claimed effect that does not reproduce independently is a reason for caution about the underlying premise, not only about safety.
None of this is a safety guarantee. MGF is an experimental peptide with no controlled human evaluation here, and material sold by research-chemical vendors is not manufactured to pharmacy standards. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence base is characterized as preclinical. MGF has a defined molecular identity as an IGF-1 splice product, and a set of cell and animal studies report roles in muscle, cartilage, and neural tissue [1][4][5]. What is absent from this corpus is any controlled human trial, so there is no clinical evidence that administering MGF produces the muscle, recovery, or other benefits it is marketed around.
"Preclinical" is a strict ceiling here, made stricter by the fact that the central muscle-proliferation claim failed an independent replication attempt [3]. Nothing here is dosing, medical, or safety guidance. Read the studies themselves, including the replication-failure report, and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 8
- Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration.
- Growth factors and muscle ageing.
- Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells.
- Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis in the aging mouse brain.
- Pretreatment with mechano growth factor E peptide attenuates osteoarthritis through improving cell proliferation and extracellular matrix synthesis in chondrocytes under severe hypoxia.
- The role of mechano growth factor in chondrocytes and cartilage defects: a concise review.
- Mechano Growth Factor Accelerates ACL Repair and Improves Cell Mobility of Mechanically Injured Human ACL Fibroblasts.
- Mechano growth factor E peptide regulates migration and differentiation of bone marrow stromal cells.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.